Seagen Shares Outstanding 2006-2021 | SGEN

Seagen shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Seagen shares outstanding for the quarter ending June 30, 2021 were 0.182B, a 4.74% increase year-over-year.
  • Seagen 2020 shares outstanding were 0.182B, a 10.14% increase from 2019.
  • Seagen 2019 shares outstanding were 0.165B, a 4.97% increase from 2018.
  • Seagen 2018 shares outstanding were 0.158B, a 10.11% increase from 2017.
Seagen Annual Shares Outstanding
(Millions of Shares)
2020 182
2019 165
2018 158
2017 143
2016 141
2015 129
2014 123
2013 122
2012 118
2011 113
2010 101
2009 91
2008 79
2007 61
2006 49
2005 42
Seagen Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 182
2021-03-31 181
2020-12-31 182
2020-09-30 182
2020-06-30 173
2020-03-31 172
2019-12-31 165
2019-09-30 168
2019-06-30 161
2019-03-31 161
2018-12-31 158
2018-09-30 159
2018-06-30 163
2018-03-31 152
2017-12-31 143
2017-09-30 148
2017-06-30 143
2017-03-31 142
2016-12-31 141
2016-09-30 141
2016-06-30 140
2016-03-31 140
2015-12-31 129
2015-09-30 128
2015-06-30 125
2015-03-31 124
2014-12-31 123
2014-09-30 124
2014-06-30 123
2014-03-31 123
2013-12-31 122
2013-09-30 122
2013-06-30 121
2013-03-31 120
2012-12-31 118
2012-09-30 118
2012-06-30 117
2012-03-31 116
2011-12-31 113
2011-09-30 115
2011-06-30 114
2011-03-31 109
2010-12-31 101
2010-09-30 101
2010-06-30 101
2010-03-31 103
2009-12-31 91
2009-09-30 93
2009-06-30 86
2009-03-31 84
2008-12-31 79
2008-09-30 80
2008-06-30 79
2008-03-31 76
2007-12-31 61
2007-09-30 66
2007-06-30 57
2007-03-31 55
2006-12-31 49
2006-09-30 51
2006-06-30 50
2006-03-31 42
2005-12-31 42
2005-09-30 42
2005-06-30 42
2005-03-31 42
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $30.241B $2.176B
Seagen Inc. is a biotechnology company. It discovers, develops and commercializes transformative cancer medicines. The company operates principally in California, Canada, Switzerland and the European Union. Seagen Inc., formerly known as Seattle Genetics Inc., is headquartered in the Seattle.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71